Podcasts about PAH

Mejorcita, hoy dedicamos el programa a hablar de algo que nos atraviesa a todas: la vivienda. Porque mientras los precios del alquiler se disparan y los fondos buitre hacen negocio, hay gente que se organiza para defender el derecho a un techo. Nos acompañan Lola del Gallego Noval y Ghita Hachemi el Aydouni, militantes de la PAH de Vallekas, un sindicato que lleva más de una década parando desahucios y plantando cara a bancos, inmobiliarias y mafias.Charlamos sobre cómo ha cambiado la lucha desde la crisis hipotecaria, el auge de los grupos de desokupación paramilitares que actúan con violencia en nuestros barrios, y desmontamos el relato del “pequeño propietario vulnerable” que tanto se repite en tertulias. También hablamos de la SAREB y campañas como #NosQuedamos, porque detrás de la crisis de vivienda hay nombres y apellidos.

Em cobertura para o Canal do Boi, o Fala Carlão marcou presença no Agromkt Summit, direto de Goiânia/GO, reunindo grandes nomes e ideias que impulsionam o marketing e a comunicação do agronegócio brasileiro.O programa contou com participações de Ricardo Nicodemos, presidente da ABMRA; Francis Barros, CEO e fundador do Agromkt Summit; Pahêdra Rios, da FrontBox; e Renato Seraphim, palestrante.Um evento que reforçou o papel da informação, da criatividade e da integração entre marcas, profissionais e produtores na construção de um agro cada vez mais forte, conectado e reconhecido.

How I Survived Meth Addiction, Lung Failure, and Found Purpose Anthony Carrasco was a meth addict by 15, and nearly dead by 35. Diagnosed with PH after years of drug use, his story spiraled from homelessness to hospice. But a double lung transplant and a deep surrender to recovery transformed everything. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @JNJInnovMed

Treating Meth-Associated PAH Without Judgment Dr. Brandon Jakubowski takes us into the underrecognized world of stimulant-induced pulmonary arterial hypertension. From misdiagnoses to under-prescribing life-saving therapies, he lays out the systemic gaps and stigmas preventing patients from getting the care they need. This Special Edition Episode Sponsored by:  Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @JNJInnovMed @UTSWMedCenter

Buhuhoooo, ihr kleinen Lakenschüttler,wenn sich der Nebel lichtet, könnt ihr die zwei Waschweiber betrachten. Sie reiben hart am Waschbrett die Gaming-Dreckwäsche und murren über ihr anstrengendes Dasein. Was sagen sie?"Ach, Essimeralda! Der grünliche Herr Miniaturweich hat wieder einmal alle Preise erhöht. Kann denn dieses Misere nicht einmal ein Ende nehmen? Nur noch Kohl und Kartoffeln. Jeden Tag." sie reibt kräftiger und ein grüner Streifen zieht sich durch das aufschäumende Wasser.Essimeralda schaut voller Gram auf ihre Freundin Janeinja und holt indes einen scharlachroten Schal aus dem Wäschekorb und legt ihn auf ihr verrottetes Waschbrett. "Hör dir mal zu, Janeinja, jammerst wie eine Dirne ohne Männlein über dein Schicksal, obwohl du es selbst gewählt hast. Wusstest doch was für ein Typ das ist, der Miniaturweich." Beide ziehen die fusseligen Brauen zusammen, schauen einander tief in die Augen und ziehen dann lautstark die letzten Rest Kohlsuppe aus der Speiseröhre und rotzen sie halb rülpsend in den Fluss, der nun in grün-roten Farben getaucht ist. "Hast ja recht, aber dein Handhimmelglück ist ja nicht besser. Nur hinter Öre her. Immer. Bringt sogar diesen gierigen Flaschner immer und immer wieder zurück. Pah, was eine Gier. Wo soll das alles enden, Essimeralda?" "Weiß ich net, Janeinja, aber was ich weiß is', das is' das wir immerhin wissen was wir wollen und nicht wollen. Und sind dabei immer ehrlich zueinander. Reden wie Gott uns das Maul in die Visage geklöppelt hat." Die Weiber drücken ihre knackenden Rücken durch und stehen knietief im Wasser. Die Wäsche hängt belanglos über den Eimern der Waschbretter, als würden sie sich nicht für das Gerede interessieren. Es stimmt auch.Die beiden schroffen Weiber schauen sich wieder an. "Wollen wir Pflaumen pflücken?"Der Wind weht. Das Wasser fließt. Die Wäsche hängt. Tropfend. Die Weiber schweigen. "Erst Podcast." "Was?" Die Zeit vergeht. Der Leuchtstreifen des Gaming ist in Sicht.Sanfte GrüßeJanina & Essi

Wer wird Träger des ersten Instagram-Rings? Das sind doch die Fragen, die uns als Gesellschaft tatsächlich nachhaltig beschäftigen sollten. Und nicht so einen langweiligen Kram wie Urheberrechte in KI-Videowelten, Donald Trump, der sich von der GenZ jetzt Wahlversprechen ermogeln möchte oder gar Regulierungen? Pah. ➡️ ZDFheute über 3 Jahre Twitterübernahme: https://www.zdfheute.de/wirtschaft/unternehmen/musk-twitter-x-3-jahre-100.html ➡️ Techcrunch über Waffeln auf Bluesky: https://techcrunch.com/2025/10/05/waffles-eat-bluesky/

The Face of Addiction Isn't Who You Think It Is Once thought to be a West Coast issue, methamphetamine-associated pulmonary hypertension is now a nationwide and global crisis. Dr. Nicholas Kolaitis reveals how building trust with meth associated-PAH patients can lead to incredible turnarounds, including sobriety, trial participation, and successful transplant. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @JNJInnovMed #PHawareMD @UCSFHospitals @LungTxptMD

Two great stories of translation science leading to beneficial drugs in terrible diseases of the heart and the Sisyphean task of predicting the need for pacing after TAVI are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Sotatercept HYPERION Trial https://www.nejm.org/doi/10.1056/NEJMoa2508170 ZENITH Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160 Evidence report on treatment for PAH https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-treatment-for-pulmonary-arterial-hypertension/ PAH Sotatercept Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2503944 II Acoramidis and ATTR Cardiomyopathy ATTRIBUTE-CM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2305434?logout=true ATTRIBUTE-CM Analysis - Substudy https://www.jacc.org/doi/10.1016/j.jacc.2025.09.013 Tafamadis Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1805689 III Pacing After TAVI Prophylactic pacemaker after TAVI https://www.jacc.org/doi/10.1016/j.jacep.2025.07.028 PROMOTE study https://doi.org/10.1016/j.hrthm.2024.12.019 Evaluation of ESC criteria on RBBB patients undergoing TAVI https://doi.org/10.1016/j.hrthm.2024.11.030 Editorial on Heart Rhythm journal papers https://www.heartrhythmjournal.com/article/S1547-5271(25)00114-6/abstract You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

How Stigma Blocks Meth-PAH Treatment and How to Stop It Patients with methamphetamine-associated-PAH often arrive at clinics already carrying heavy shame. But shame shouldn't be part of their medical history. In this compelling episode, Dr. Peter Leary explains how stigma—from both society and providers—can delay life-saving care. Learn how a change in mindset, language, and compassion can transform outcomes for a neglected and growing patient population. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @uwepidemiology  @JNJInnovMed

The Hidden Epidemic: Meth and PHMeth-Associated PAH is on the rise across the United States, yet many patients are not receiving the treatment they need. Dr. Vinicio de Jesus Perez discusses the shifting demographics of meth users, the challenges of treating addiction in cardiopulmonary care, and the need for compassionate, stigma-free screening. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @PHatStanford  @Viniciodjperez  @JNJInnovMed

When six months is the best a doctor can offer, hope feels like a cruel joke. In this Breakdown edition of Sickboy, we dig into Pulmonary Arterial Hypertension (PAH)—a rare disease that once meant certain death but now has science flipping the script.Through narration and three candid interviews, this audio doc traces PAH's path from despair to possibility. Jane shares what it's like to have her lungs hijacked in her twenties. Dr. David Langleben, who built Canada's first pulmonary hypertension clinic, walks us through decades of grim prognoses. And Jamie Myra of PHA Canada explains why delayed diagnosis is still PAH's deadliest trick. But then comes the plot twist: a new therapy called Sotatercept, a treatment that doesn't just slap a Band-Aid on symptoms but actually targets the root cause. For doctors who've watched patients run out of time, it's nothing short of a game changer.The Breakdown is a new addition to the Sickboy's format! An audio documentary where we crack open one illness at a time and make sense of it with heart, humour, and the occasional “WTF.”Shout out to PHA Canada! This first Breakdown proves that even in the heaviest stories, hope still gets the last word.For more information on how you can help please visit https://www.phacanada.ca/Follow Sickboy: Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDN

When six months is the best a doctor can offer, hope feels like a cruel joke. In this Breakdown edition of Sickboy, we dig into Pulmonary Arterial Hypertension (PAH)—a rare disease that once meant certain death but now has science flipping the script.Through narration and three candid interviews, this audio doc traces PAH's path from despair to possibility. Jane shares what it's like to have her lungs hijacked in her twenties. Dr. David Langleben, who built Canada's first pulmonary hypertension clinic, walks us through decades of grim prognoses. And Jamie Myra of PHA Canada explains why delayed diagnosis is still PAH's deadliest trick. But then comes the plot twist: a new therapy called Sotatercept, a treatment that doesn't just slap a Band-Aid on symptoms but actually targets the root cause. For doctors who've watched patients run out of time, it's nothing short of a game changer.The Breakdown is a new addition to the Sickboy's format! An audio documentary where we crack open one illness at a time and make sense of it with heart, humour, and the occasional “WTF.”Shout out to PHA Canada! This first Breakdown proves that even in the heaviest stories, hope still gets the last word.For more information on how you can help please visit https://www.phacanada.ca/Follow Sickboy: Instagram: https://www.instagram.com/sickboypodcastTiktok: https://www.tiktok.com/@sickboypodcastDiscord: https://discord.gg/expeUDN

Dr. John Kingrey exposes the rising crisis of meth-associated pulmonary hypertension, a condition spreading fast across the U.S. He challenges misconceptions, highlights urgent research, and stresses the need for compassion in treating both PAH and addiction. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @integrishealth @teamphhope @JNJInnovMed #phawareMD

A 200 Mile Journey from LA to San Diego to Raise Awareness for PH When Eric Borstein collapsed in his bedroom in 2020, doctors gave him just months to live. Instead, he fought back with walking, mental health, and the support of his community. Now, he's leading a movement, raising hundreds of thousands for pulmonary hypertension research, and walking 200 miles down the California coast to prove hope has no limits. Learn more about the 2nd Annual Where is EB? 5K Walk and Fundraiser September 7, 2025 Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware  Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @teamphhope  @where_is_eb @DJLisaFoxx  

Merriam-Webster's Word of the Day for August 31, 2025 is: simpatico • sim-PAH-tih-koh • adjective Simpatico typically describes two or more people or things with shared qualities, interests, etc. It can also describe someone who is agreeable or likeable. // Even though they weren't always simpatico with regard to the direction of their company, the pair managed to be successful partners for more than 35 years. See the entry > Examples: “From the early 2010s, when he was a young teen rapper in Chicago ... Chief Keef was flooding his Instagram with self-documentation, all of which is essentially gone now. Enter Eduard Taberner Pérez, an amateur archivist and professional graphic designer, who compiled ‘Sosa Archive,' a limited-run art book that gathers several thousand photos pulled from Keef's Instagram, presenting then in visually simpatico grids of 12.” — Jon Caramanica, The New York Times, 5 Mar. 2025 Did you know? Simpatico, which comes ultimately from the Latin noun sympathia, meaning “sympathy,” was borrowed into English from both the Italian simpatico and Spanish simpatico. In those languages, the word has been chiefly used to describe people who are well-liked or easy to get along with. Early uses of the word in English reflected those of their forebears, as in Henry James's 1881 novel The Portrait of a Lady, in which one character says of another's dying cousin, “Ah, he was so simpatico. I'm awfully sorry for you.” In recent years, however, the word has gained an additional sense describing things or people who get along well or work well together.

It's Wednesday, August 20th, A.D. 2025. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark Muslim Nigerians killed 7,000 Christians this year A Nigerian-based nonprofit reports Islamic extremists have killed over 7,000 Christians in the country so far this year. The International Society for Civil Liberties and Rule of Law also found that nearly 8,000 Christians were violently seized and abducted.  The report notes this translates into “an average of 30 Christian deaths per day and more than one per hour.” Since 2009, Jihadists in Nigeria have killed over 125,000 Christians and destroyed nearly 20,000 church buildings.  Please pray for our brothers and sisters in Christ in Nigeria. The country is ranked seventh on the Open Doors' World Watch List of the most difficult countries to be a Christian.  Psalm 14:4 asks, “Have all the workers of iniquity no knowledge, who eat up my people as they eat bread, and do not call on the LORD?” Absurd charges dropped against Scottish pro-life grandmother Authorities in Scotland dropped charges against a 75-year-old grandmother who was arrested for holding a sign near an abortion mill.  Back in February, Rose Docherty held a sign that read: “Coercion is a crime, here to talk, only if you want.” Officials arrested her for violating a “buffer zone” law that restricts free expression near abortion mills. Docherty reacted to her case being dropped. She said, “This is a victory not just for me, but for everyone in Scotland who believes we should be free to hold a peaceful conversation.” Conservative Canadian Pierre Poilievre wins election In Canada, Conservative Leader Pierre Poilievre (pronounced PAH-lee-ev) won a special election in the province of Alberta on Monday.  Poilievre heads back to Canada's parliament after losing his seat earlier this year. He will continue his work as the opposition leader against Canada's ruling Liberal Party. Listen to comments from Poilievre. POILIEVRE: “We will work together. We will fight together. We will sacrifice together to restore the opportunity that our grandparents left for us, so that we can leave it for our grandchildren, so that we can once again restore a country that is strong, self-reliant and sovereign. That is why we stay united. That is why we go forward. May God keep our land glorious and free.” Trump wants to end mail-in ballots In the United States, President Donald Trump said Monday that he wants to end mail-in ballots as well as voting machines. Listen to comments from Trump.  TRUMP:  “You can never have a real democracy with mail in ballots. We, as a Republican Party, are going to do everything possible that we get rid of mail-in ballots. We're going to start with an executive order, that's being written right now by the best lawyers in the country, to end mail-in ballots because they're corrupt.” Trump wrote on Truth Social, “With their HORRIBLE Radical Left policies, like Open Borders, Men Playing in Women's Sports, Transgender and ‘WOKE' for everyone, and so much more, Democrats are virtually Unelectable without using this completely disproven Mail-In SCAM.” Bank of America will stop "debanking" conservatives The New York Post reports that Bank of America scrapped a rule used to “debank” conservatives. Major banks have also used the rule to deny services to religious groups, especially Evangelical ones.  JP Morgan Chase dropped the rule last year. Bank of America finally followed suit.  Jeremy Tedesco with Alliance Defending Freedom said, “Over the past two years, ADF and our partners in both the private and public sectors have repeatedly engaged with Bank of America's leadership to advocate for this change.” Fewer Americans are moving The Wall Street Journal reports that U.S. domestic migration rates are down. Only 7.9% of Americans relocated to a new town or city last year, down from about 20% in the 1950s and 60s. The rate has been steadily declining since then. People are also moving less within their own county. That rate is down 47% over the past three decades.  The falling domestic migration rates are associated with high mortgage rates, dual-income households, an aging population, and remote job opportunities.  Church-engaged Christians have less stress, anxiety, and loneliness And finally, the American Bible Society released the fifth chapter of its State of Bible: USA 2025 report. The chapter measured church engagement as the level of a person's involvement in the life, mission, and community of a local church. Only 34% of self-identified Christians attend church weekly. In terms of generations, Gen Z had the lowest levels of church engagement. Women, married people, Evangelicals, and people in small cities were more likely to be highly engaged with their church. John Plake with the American Bible Society said, “Our survey shows that church-engaged Christians have significantly less stress, less anxiety, less loneliness, and more hope.” Hebrews 10:24-25 says, “And let us consider one another in order to stir up love and good works, not forsaking the assembling of ourselves together, as is the manner of some, but exhorting one another, and so much the more as you see the Day approaching.” Close And that's The Worldview on this Wednesday, August 20th, in the year of our Lord 2025. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

In the second episode of our Rare Lung Diseases podcast mini-series, host Saranya Ravindran delves into the complexities of pulmonary arterial hypertension (PAH) with Neal Chaisson, Assistant Professor of Medicine at the Cleveland Clinic. Chaisson shares insights into why PAH remains under-recognised, the nuances of detection and diagnosis, and what the latest advancements mean for patients and clinicians. The discussion covers everything from early warning signs to future directions in PAH management and research. Timestamps: 01:05 – Diagnostic workflows 03:58 – Non-invasive tools 05:37 – Right heart catheterisation values 09:05 – Vasoreactivity testing 11:10 – Genetic testing 13:08 – Innovative diagnostics

In the second episode of our Rare Lung Diseases podcast mini-series, host Saranya Ravindran delves into the complexities of pulmonary arterial hypertension (PAH) with Neal Chaisson, Assistant Professor of Medicine at the Cleveland Clinic. Chaisson shares insights into why PAH remains under-recognised, the nuances of detection and diagnosis, and what the latest advancements mean for patients and clinicians. The discussion covers everything from early warning signs to future directions in PAH management and research. Tinestamps: 00:45 – PAH management 03:05 – Hypoxia 06:42 – Decompensated PAH 10:06 – At-home treatments 12:44 – Multidisciplinary teams 14:50 – Novel therapies

Dr. John Granton, a critical care and transplant physician at Toronto General Hospital, shares his journey in pulmonary hypertension and lung transplantation, detailing the groundbreaking advancements in transplant technology. He discusses the evolution of lung preservation methods, the challenges of chronic rejection, and the hope for longer-lasting transplants. With a passion for improving patient outcomes, Dr. Granton envisions a future where transplant becomes obsolete—replaced by treatments that cure underlying diseases. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @UHN @teamphhope #phawareMD #PHILD #transplant @phacanada

In the second episode of our Rare Lung Diseases podcast mini-series, host Saranya Ravindran delves into the complexities of pulmonary arterial hypertension (PAH) with Neal Chaisson, Assistant Professor of Medicine at the Cleveland Clinic. Chaisson shares insights into why PAH remains under-recognised, the nuances of detection and diagnosis, and what the latest advancements mean for patients and clinicians. The discussion covers everything from early warning signs to future directions in PAH management and research. 

In the second episode of our Rare Lung Diseases podcast mini-series, host Saranya Ravindran delves into the complexities of pulmonary arterial hypertension (PAH) with Neal Chaisson, Assistant Professor of Medicine at the Cleveland Clinic. Chaisson shares insights into why PAH remains under-recognised, the nuances of detection and diagnosis, and what the latest advancements mean for patients and clinicians. The discussion covers everything from early warning signs to future directions in PAH management and research.  Timestamps:   Part 1:   01:00 – What is PAH  02:34 – Risk factors  04:21 – Misdiagnoses  07:13 – Pathophysiology  10:44 – World Symposium classification 

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today, we're focusing on an often-overlooked peptide called VIP, short for Vasoactive Intestinal Peptide. The name might sound technical, but this peptide plays some important roles in the body. It helps regulate inflammation, supports nerve function, improves blood flow by relaxing blood vessels, and may even have benefits for things like chronic pain, including back pain. Let's get into it. What is VIP? We've talked about VIP before on a previous podcast, but it's been awhile and I'd like to start with the basics as a refresher.  VIP is a 28-amino acid neuropeptide that acts like a signaling molecule in both the central and peripheral nervous systems. Think of it like a chemical messenger that can influence a lot of different body systems. VIP belongs to the glucagon/secretin peptide superfamily, and it's found throughout the body, including your brain, intestines, lungs, and immune cells. Now, what does VIP actually do? Well it does quite a bit. VIP works by binding to specific receptors on cells—called VPAC1 and VPAC2—which trigger a chain reaction inside the body through something known as the cyclic AMP pathway. Once activated:  It relaxes smooth muscles, which helps open up blood vessels (vasodilation) and airways (bronchodilation) It stimulates secretion of water and electrolytes in places like the gut and pancreas—so yes, it helps with digestion too It's a major immune modulator, calming inflammation by regulating immune cell behavior  Neuroprotective role, supporting the survival and adaptability of neurons VIP in Medicine – What's the Buzz? VIP has been studied in a variety of conditions. Inflammatory diseases like rheumatoid arthritis and Crohn's Neurodegenerative conditions like Alzheimer's and Parkinson's Autoimmune diseases like osteoarthritis Respiratory conditions like pulmonary arterial hypertension (PAH), asthma, and chronic obstructive pulmonary disease (COPD) or due to mold toxicity But today, we're zooming in on something more tangible for a lot of people—back pain. VIP and Back Pain – What Do We Know? Let's get into the science here. VIP has recently caught attention for its potential role in intervertebral disc degeneration, which is one of the top causes of chronic low back pain. A 2024 study found that VIP receptors were significantly reduced in degenerated human discs—which is kind of a red flag. When VIP was given to mice for four weeks, researchers saw slowed degeneration, better structural proteins like aggrecan, and overall healthier discs on imaging. Promising, right? But here's the catch—this was a preclinical animal study. We still need human trials to confirm it works outside the lab. VIP and Joint Pain And when it comes to VIP and joint pain, there's a bit more research on VIP and osteoarthritis, especially when the spine is involved. In OA models, VIP was shown to lower pro-inflammatory cytokines—those molecules that contribute to pain and make joints hurt. But here's where it gets complicated: some studies report that VIP accumulation in joints might actually worsen pain. So... it's a bit of a paradox. So what's the takeaway? VIP can be helpful—but its role in pain management seems to depend on how much, where, and what kind of pain we're talking about. VIP in Peptide Therapy – Real-World Use? In peptide clinics—especially those using integrative or regenerative medicine approaches—VIP is sometimes part of treatment protocols for nerve-related pain and inflammation. It's often paired with other peptides like BPC-157 and TB-500. You can find some clinics that list VIP as a go-to for chronic pain, including back pain. But here's the reality check, clinical data is limited, success is anecdotal, it's pricey and results can vary from person to person. So while VIP might help reduce inflammation and slow tissue degeneration, it's not a substitute for tried-and-true pain management peptides like BPC-157. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

Dr. Tijana Milinic and Lia Barros, DNP, from the University of Washington take a deep dive into the world of pulmonary arterial hypertension (PAH) clinical trials and discuss why diversity and inclusion matter. They explore the hidden biases in medical research and the real-world consequences of exclusion. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @uwepidemiology  #phawareMD

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-patient-experiences-and-pah-perspectives-vary-across-regions-and-cultures-worldwide/33245/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-travel-with-pah-logistics-medications-oxygen-and-emergency-preparedness/33237/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-role-in-clinical-research-and-contributions-to-pah-patient-perspectives/33244/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-in-clinical-practice-impacting-treatment-decisions/33243/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-latest-patient-centered-recommendations-from-the-7th-world-symposium-on-ph/33236/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/aligning-pah-treatment-plans-with-key-care-goals-and-your-patients-priorities/33238/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-palliative-care-in-pulmonary-hypertension/33239/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-reported-outcome-measures-proms-valuable-insights-into-the-lived-experience-of-pah/33240/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/what-challenges-and-triumphs-do-patients-face-while-living-with-pah/33242/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-comparison-of-proms-and-how-to-use-them-in-clinical-practice-for-pah/33241/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-patient-experiences-and-pah-perspectives-vary-across-regions-and-cultures-worldwide/33245/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-role-in-clinical-research-and-contributions-to-pah-patient-perspectives/33244/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/proms-in-clinical-practice-impacting-treatment-decisions/33243/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/what-challenges-and-triumphs-do-patients-face-while-living-with-pah/33242/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-comparison-of-proms-and-how-to-use-them-in-clinical-practice-for-pah/33241/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-reported-outcome-measures-proms-valuable-insights-into-the-lived-experience-of-pah/33240/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-palliative-care-in-pulmonary-hypertension/33239/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/aligning-pah-treatment-plans-with-key-care-goals-and-your-patients-priorities/33238/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-travel-with-pah-logistics-medications-oxygen-and-emergency-preparedness/33237/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

CME credits: 1.00 Valid until: 15-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-latest-patient-centered-recommendations-from-the-7th-world-symposium-on-ph/33236/ Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Dr. Lana Melendres-Groves dives into her research on racial and ethnic disparities in PAH treatment. From differences in medication access to the role of social determinants of health, she explores how systemic barriers impact care and what steps can be taken to ensure equity and inclusivity in PAH management. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @UNMHSC #phawareMD

Dr. Roham Zamanian, discusses the concept of "disease modification" in the treatment of pulmonary hypertension. He describes how this idea emerged from discussions with colleagues about the future of pulmonary hypertension therapies, and the potential for treatments to impact the underlying disease process beyond just reducing pulmonary artery pressures. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @PHatStanford @docroham @JNJInnovMed    

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for June 16-22, 2025: Pemvidutide Shows Significant MASH Effects, Weight Loss at 24 Weeks in Phase 2b IMPACT Trial Topline phase 2b data show pemvidutide achieved significant rates of MASH resolution and fibrosis improvement alongside meaningful weight loss at 24 weeks, positioning it as a promising candidate for metabolic liver disease treatment. FDA Approves Belimumab (Benlysta) Autoinjector for Pediatric Lupus Nephritis The FDA approved a belimumab autoinjector for at-home subcutaneous use in children as young as five with active lupus nephritis, providing the first approved biologic self-injection option for pediatric SLE and LN. Phase 3 Trial Results Announced for Sotatercept-csrk in Pulmonary Arterial Hypertension Positive phase 3 results show sotatercept-csrk added to background therapy reduced time to clinical worsening events in adults with PAH, supporting its potential as an effective treatment for this high-risk population. Compass Pathways' COMP360 Psilocybin Shows Benefit in Phase 3 TRD Trial COMP360 psilocybin demonstrated a significant reduction in depression symptom severity in treatment-resistant depression, meeting the primary endpoint in a pivotal phase 3 trial. Once-Monthly Obesity Drug, MariTide, Achieves Weight Loss Up to 16% at 1 Year Phase 2 data indicate once-monthly MariTide induces substantial weight loss of up to 16% over one year, with additional improvements in glycemic control, highlighting its promise for obesity and type 2 diabetes management.

Dr. Rodolfo Estrada, is a seasoned pulmonologists currently at UT Health San Antonio with significant experience in the management of patients with different forms of pulmonary hypertension. In this episode, Dr. Estrada will discuss the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder and why it might be a good option for some PAH and PH-ILD patients. This Special Edition episode is sponsored by Liquidia. Please see the Important Safety Information following this podcast. The Prescribing Information and Instructions for Use for YUTREPIA (treprostinil) inhalation powder are available at YUTREPIA.com.  YUTREPIA is approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise. Please see the Important Safety Information in the show notes. The Prescribing Information and Instructions for Use for YUTREPIA are available at YUTREPIA.com. Learn more about the INSPIRE study. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp @REstradaMD @UTHealthSA IMPORTANT SAFETY INFORMATION Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you: Have low blood pressure Have or have had bleeding problems Have asthma or chronic obstructive pulmonary disease (COPD) Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other. Especially tell your healthcare provider if you take: Medicines used to treat high blood pressure or heart disease Medicines that decrease blood clotting (anticoagulants) Water pills (diuretics) Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®) What are the possible side effects of YUTREPIA? This product can cause serious side effects, including: Low blood pressure (symptomatic hypotension). If you have low blood pressure, this product may lower your blood pressure more. Bleeding problems. This product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants). The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1–800-FDA-1088. The risk information provided here is not comprehensive. To learn more about YUTREPIA, talk with your healthcare provider. Please see Full Prescribing Information for YUTREPIA and Instructions for Use. For additional information, call 1–888–393–5732.

Seth Hall, MBA, RRT, takes listeners on a journey through the past, present, and future of inhaled therapies. Discover how these treatments have evolved, the life-changing benefits they offer, and the revolutionary technologies that could redefine outcomes for PAH and PH-ILD patients. This Special Edition episode is sponsored by Liquidia. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp #PRINTTechnology